
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 177-Lu PentixaTher
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pentixapharm Advances PentixaTher to Fourth Dose in AML Trial
Details : Company's s CXCR4-targeting radiolabeled candidate PentixaTher has advanced to the fourth dose level in the investigator-initiated pentilula Phase 1/2 study in acute myeloid leukemia (AML).
Product Name : PentixaTher
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
September 26, 2025
Lead Product(s) : 177-Lu PentixaTher
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 177-Lu PentixaTher
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lu177-PentixaTher Trial Begins for AML and ALL, Supporting Radiotherapy Evidence
Details : Lu177-PentixaTher is a novel radiopharmaceutical therapy, being investigated in adults for relapsed/refractory CXCR4 positive acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 21, 2024
Lead Product(s) : 177-Lu PentixaTher
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Y90-PentixaTher
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : BankM AG
Deal Size : $22.0 million
Deal Type : Public Offering
Pentixapharm Scores $22M in IPO to Advance Radiopharma Trials
Details : The proceeds will focus on the clinical development and approval of company's lead candidates Ga68-PentixaFor and Y90-PentixaTher.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 03, 2024
Lead Product(s) : Y90-PentixaTher
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : BankM AG
Deal Size : $22.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GT-001
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Glycotope
Deal Size : Undisclosed
Deal Type : Acquisition
Pentixapharm Acquires Target Discovery Business of Glycotope
Details : Through the acquisition, Pentixapharm will leverage the Glycotype portfolio of preclinical antibodies against multiple oncology including GT-001, which is being evaluated for breast and lung cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 03, 2024
Lead Product(s) : GT-001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Glycotope
Deal Size : Undisclosed
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 90-Y PentixaTher
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients
Details : 90-Y PentixaTher is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Central Nervous System Lymphoma.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
November 15, 2023
Lead Product(s) : 90-Y PentixaTher
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma
Details : 68-Ga Pentixafor is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lymphoma, B-Cell, Marginal Zone.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
November 09, 2023

[68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients
Details : 68-Ga PTF is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Central Nervous System Lymphoma.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
February 03, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 68-Ga Pentixafor
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Memorial Sloan Kettering Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Details : 68-Ga Pentixafor is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, Non-Hodgkin.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
October 26, 2021
Lead Product(s) : 68-Ga Pentixafor
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Memorial Sloan Kettering Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pentixafor
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Elsa Eckert Life Science Accelerator
Deal Size : $16.2 million
Deal Type : Series A Financing
PENTIXAPHARM Secures € 15 Million Series A Financing
Details : Funding is dedicated for a phase II trial of the imaging compound PentixaFor and for a phase I trial of the therapeutic compound PentixaTher in Central Nervous System Lymphoma.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
February 06, 2020
Lead Product(s) : Pentixafor
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Elsa Eckert Life Science Accelerator
Deal Size : $16.2 million
Deal Type : Series A Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Myelo001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia
Details : Myelo001 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chemotherapy-induced Neutropenia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 26, 2016
Lead Product(s) : Myelo001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
